Background: Antiretrovirals (ARVs) are the molecules used in the fight against infection by the Human Immunodeficiency Virus (HIV). Their main objective is to stop the virus from replicating and thus allow the immune system to recover. In 2001, the program to fight against HIV/AIDS United Nations (UNAIDS) and its partners has decided to strengthen the pharmaceutical channel and improve access to good quality care. Thus ARV quality control is recommended. Objective: The objective of this work was to monitor the quality of ARVs distributed in Kinshasa. Methodology: In this work, UV-visible spectrophotometry is used for the analysis of ARVs presented in simple form distributed in the city of Kinshasa. Results: The results of this work show that the stated and analyzed ARVs contain active ingredients; there is no placebo. Ten percent of these ARVs are non-compliant with regard to dosing of the active test. Conclusion: These results confirm the need to control these drugs to protect patients from adverse consequences related to their poor quality.
Introduction
Antiretrovirals (ARVs) are molecules used to fight against the Human Immunodeficiency Virus (HIV) infection [1] . The main objective of these molecules is to slow down the virus replication and thus allow the immune system to recover, to make the plasmatic Viral Load (VL) undetectable (<50 RNA/ml copies) which allows better immune restoration and reduces the risk of selection of resistant virus [1] .
In 2001, the United Nations program to fight against HIV/AIDS (UNAIDS) and its partners has addressed the problems of drug quality in their generic form [2] . This program is more interested in ARV in resource limited countries where generics are often of dubious quality and quantitatively under dosage recommendation [2] [3] . UNAIDS has decided to strengthen the pharmaceutical channel of these countries and improve access to quality care for all patients because poverty and disorganization of the pharmaceutical sector are the main reasons for the phenomenon of counterfeiting [4] . The qualitative and quantitative analysis of ARV is therefore recommended. This must be done regularly, internally and externally, and be reported to the appropriate authorities [1] . It should be performed throughout the pharmaceutical supply circuit; from manufacture to use. At reception and storage point, each batch of ARVs must be subject to quality control [1] .
The National Programs against HIV/AIDS (PNMLS and PNLS) are the main national bodies in the fight against the epidemic and the care of People Living with HIV (PLHIV) in the country. Their main strategies are focused on education and outreach; free voluntary testing in different centers, management, therapeutic monitoring and psychosocial assistance for eligible patients [5] .
In the Democratic Republic of Congo (DRC), the most commonly used molecules, as of 2012, are: Abacavir (ABC), Efavirenz (EFV), Lamivudine (3TC), Lopinavir boosted by Ritonavir (LPV/r), Nevirapine (NVP), Stavudine (d4T) and Zidovudine (ZDV) [5] . All these molecules are pre-qualified generic by the World Health Organization (WHO); however, pre-qualification does not exclude quality control in the provision for use by the patient [2] .
This study aimed to control the quality of some ARVs distributed in Kinshasa [6] . The targeted molecules in this study were: Abacavir (ABC), Efavirenz (EFV), Nevirapine (NVP) and Zidovudine (ZDV).
Materials and Methods

Framework
This study was conducted in the period from the August 20, 2013 to January, 20 
Analyzed Molecules
The molecules analyzed in this study are presented in Table 1 . They were freely donated by different monitoring centers for HIV patients in Kinshasa [5] .
Selection of Samples
The sample selection was made randomly in the received packages. Twenty pills of each drug were used for the analysis.
Materials
The UV-Visible spectrophotometer (HP/Agilent 8453) with Agilent Technologies ChemStation software (Gyeonggi-do, South Korea) was used for the study.
The wavelengths used were 285 nm for Abacavir (ABC) [7] and Nevirapine (NVP) [7] [8], 266 nm for Zidovudine (ZDV) [7] [9] and 254 nm for Efavirenz (EFV) [7] . Friabilimeter was of Erweka brand and tablet disintegration was 
Pharmaco-Technical Tests
Performed according to the recommendations of the European Pharmacopoeia 8.1 [10], the friability test was performed by weighing a given number of pills equivalent to 6.5g. This assay allows estimating the strength of the tablets during the packaging operations, and possible coating and transport. The pills disintegration was completed in ultrapure water placed at 37˚C for 15 minutes to determine the ability to disintegrate in a prescribed time in liquid medium.
Methods
The friability assays, the chemo-physical assays and the spectrophotometric assays used in this study are all described in the literature [6] - [14] . The standards assay being set from 90.0% to 110.0%.
Preparation of Standard Solutions
Standard solutions of 1 mg/ml were prepared from the reference chemicals of different molecules each dissolved in 100 ml of solvent (methanol for EFV, NVP and ZDV; ultrapure water for ABC). Different concentrations (5 μg/ml, 10 µg/ml and 15 μg/ml) were used to draw the calibration line in the type of y = ax + b (a: as the slope of the equation; b: as origin coordinate; x: as the concentration; y: as the analytical response or absorbance). The coefficient of determination (R 2 ) was used as a quality indicator for the calibration slope. After the linearity of the calibration slope was confirmed, it was used to calculate the sample concentrations.
Results and Discussion
The samples used in this study were provided without charge by different centers of treatment and supported for People Living with HIV/AIDS in Kinshasa. Table 1 provides information on the various molecules used; he presents the name of the drug, the International Nonproprietary Name (INN), the manufacturer's name, the batch number and the manufacturer's country of origin. All these molecules are manufactured by Indian pharmaceutical companies (Matrix Lab Limited, Aurobindo Pharma Limited, Ranbaxy, Hetero Labs Limited, Cipla and Strides Arcolab Limited). Table 2 shows the results of tests friability obtained for the 10 analyzed specialties. All molecules were analyzed in accordance with a loss of weight less than 1% by. These tablets can therefore hold up well during packaging and transpor-E. N. Kamangu et al.
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OALib Journal tation. Table 3 presents the results of the disintegration test of the 10 molecules tested. This Physicochemical test provides information on the potential release of active ingredient from the oral dosage form in a required time and good disintegration of such tablets in the gastrointestinal tract because the disintegration promotes bioavailability of drug [6] [10]. These molecules were compliant in relation to disaggregation time; they all have a time inferior than 15 minutes.
Further then, the molecules were identified through their Ultra Violet (UV) spectra through the methods used. These UV spectra are shown in Figure 1 for all 4 analyzed molecules. In all samples tested, there was concordance between the standard UV spectrum and that found in the sample, allowing confirming the identity of the different molecules analyzed. They all contain the active principle as declared by the manufacturer.
After determination of UV spectra, the molecules were quantified using the calibration lines. The results of the quantification of the molecules are shown in Table 2 . Results of the friability assays with the studied drugs. Table 3 . Results of disintegration assays with the studied drugs. These results are similar to those described in our environment [6] , ARVs distributed in Kinshasa are of good quality, but there is still 1 set that captures the attention. Hence the need to widely implement quality control of ARVs.
Conclusion and Perspective
The objective of this study was to monitor the quality of antiretroviral medicines presented in non-combined form distributed in Kinshasa using UV-Visible spectrophotometry. The molecules used for this study are: Abacavir, Efavirenz, Nevirapine and Zidovudine.
The results obtained from the 10 analyzed molecules show that all these products contain the active ingredients stated and satisfy to friability testing and disintegration of tablets. However, a molecule (10%) is non-compliant in accordance with dosing tests, which poses a risk of toxicity for the patient. This demonstrates the need for quality control of ARVs prior to distribution in Kinshasa.
